	US 12,234,272 B2
	Pharmaceutical preparation comprising recombinant HCG
Ian Cottingham, St. Prex (CH); Daniel Plaksin, St. Prex (CH); and Richard White, San Diego, CA (US)
Assigned to Ferring B.V., Hoofddorp (NL)
Filed by Ferring B.V., Hoofddorp (NL)
Filed on Mar. 30, 2022, as Appl. No. 17/709,296.
Application 17/709,296 is a continuation of application No. 16/709,810, filed on Dec. 10, 2019, granted, now 11,292,824.
Application 16/709,810 is a continuation of application No. 15/586,010, filed on May 3, 2017, granted, now 10,526,390.
Application 15/586,010 is a continuation of application No. 14/283,904, filed on May 21, 2014, granted, now 9,676,835.
Application 14/283,904 is a continuation of application No. 13/500,274, granted, now 8,975,226, previously published as PCT/GB2010/001854, filed on Oct. 4, 2010.
Claims priority of application No. 09252360 (EP), filed on Oct. 5, 2009.
Prior Publication US 2022/0340634 A1, Oct. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/575 (2006.01); A61K 38/16 (2006.01); C07K 14/59 (2006.01); C12P 21/00 (2006.01)

CPC C07K 14/575 (2013.01) [C07K 14/59 (2013.01); C12P 21/005 (2013.01); A61K 38/16 (2013.01)]

5 Claims

1. A pharmaceutical composition comprising recombinant human chorionic gonadotrophin (rhCG), wherein the rhCG includes α2,3-sialylation and α2,6-sialylation and mono-(1S), di-(2S), tri-(3S) and tetra-(4S) sialylated glycan structures, wherein the composition is an injectable aqueous solution.